Preview

Ural Medical Journal

Advanced search

Pulmonary tuberculosis in patients with different types of diabetes mellitus: course and efficacy of treatment

https://doi.org/10.25694/URMJ.2018.05.51

Abstract

The aim of the study was a comparative analysis of the features of the course and efficacy of the treatment of pulmonary tuberculosis in patients with different types of diabetes mellitus (DM). 287 patients with pulmonary tuberculosis were examined, which were divided into 3 groups. The first group included 69 patients with pulmonary tuberculosis in combination with type 1 diabetes (DM1). The second group consisted of 87 patients with pulmonary tuberculosis in combination with type 2 diabetes (DM2). The third group consisted of 131 patients with pulmonary tuberculosis without diabetes mellitus. It was found that pulmonary tuberculosis in patients with type 1 diabetes mellitus and in patients without diabetes was predominantly detected at the age of 20 to 39 years, and in type 2 diabetes, on the contrary - over the age of 40 years. A comparative analysis of the clinical forms of pulmonary tuberculosis showed that tuberculum were significantly more frequent among patients with type 1 and type 2 diabetes than those without diabetes. Distraction in lung tissue was observed in most patients in all three groups. In patients with combined DM, cavities with diameters less than 2 cm was more often observed. In patients with tuberculosis without DM, cavities with sizes from 2 to 4 cm were more often detected. M. tuberculosis positive sputum was observed in the majority of patients in all three groups, but significantly more often in patients with DM2. According to the spectrum of drug resistance, compared groups did not differ significantly. Negativation of sputum in 6 months was detected in 77,5% of patients with DM1, in 88,9% of patients with DM2 and 85,7% of patients without DM. Closing the cavity in lung in six month was detected in 38,8% of patients with DM1, in 59,3% of patients with DM2 and 61,0% of patients without DM.

About the Authors

O. G. Komissarova
ФГБНУ «Центральный научно-исследовательский институт туберкулеза»; Российский национальный исследовательский медицинский университет (РНИМУ) им. Н.И.Пирогова
Russian Federation


R. Yu. Abdullaev
ФГБНУ «Центральный научно-исследовательский институт туберкулеза»
Russian Federation


S. V. Aleshina
ФГБНУ «Центральный научно-исследовательский институт туберкулеза»
Russian Federation


A. E. Ergeshov
ФГБНУ «Центральный научно-исследовательский институт туберкулеза»
Russian Federation


References

1. World Health Organization, Global tuberculosis report 2017. http://www.who.int/tb/publications/global_ report/en/ (Accessed 2 August 2017)

2. Нечаева О.Б. Эпидемиологических показателей по туберкулезу за 2016 год. [Электронный ресурс]: http://www.mednet.ru/ru/czentr-monitoringa-tuberkuleza.html

3. Шестакова М.В., Сухарева О.Ю. Диагностика и выбор метода лечения сахарного диабета 2 типа. Клиническая фармакология. 2018; 27(2): 3-9.

4. Critchley J.A., Restrepo B.I., Ronacher K. et al.Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes. Part 1: Epidemiology and Clinical Management //Chest -2017. - Vol.152. - p.165-173.

5. IDF Diabetes Atlasт Eighth Edition 2017. IDF [Official website]. http://www. idf.org/diabetesatlas

6. Каминская Г.О., Абдуллаев Р.Ю. Патофизиологические предпосылки неблагоприятного влияния сахарного диабета на течение туберкулеза легких. Туберк. и бол. легких. 2014; 3:5-10.

7. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахар ный диабет 2017; 20(1):13-41

8. Комиссарова О.Г., Абдуллаев Р.Ю., Михайловский А.М. Сахарный диабет как фактор риска развития туберкулеза: патофизиологические аспекты. Медицинский альянс. 2017 3:28-34

9. Ronacher K., van Crevel R., Critchley J.A. et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mechanisms. Chest - 2017. -152(1): 174-180. doi: 10.1016/j.chest.2017.02.032

10. Комиссарова О.Г., Абдуллаев Р.Ю., Коняева О.О., Михайловский А.М. Распространенность, клинические проявления и эффективность лечения туберкулеза у больных сахарным диабетом. Врач. 2017; 2: 24-8

11. Смурова Т.Ф., Ковалева С.И. Туберкулез и сахарный диабет. М.:Медкнига, 2007; 317с

12. Jeon C.Y., Murray M.B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008; 5 (7): e152.

13. Дедов И.И. Инновационные технологии в лечении и профилактике сахарного диабета и его осложнений. Сах. диабет. 2013; 3:4-10.

14. Pablos-Méndez A., Blustein J., Knirsch C.A. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am. J. Public Health. 1997; 87 (4): 574-579.

15. Bashar M., Alcabes P., Rom W.N., Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest. 2001;120 (5):1514-19.

16. Fisher-Hoch S.P., Whitney E., McCormick J.B. et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand. J. Infect. Dis. 2008; 40(11-12): 888-93.


Review

For citations:


Komissarova OG, Abdullaev RY, Aleshina SV, Ergeshov AE. Pulmonary tuberculosis in patients with different types of diabetes mellitus: course and efficacy of treatment. Ural Medical Journal. 2018;(8):53-58. (In Russ.) https://doi.org/10.25694/URMJ.2018.05.51

Views: 392


ISSN 2071-5943 (Print)
ISSN 2949-4389 (Online)